Biogen has offered to purchase Sage’s outstanding shares for $7.22 each, according to a securities filing from Friday. The proposal values Sage at around $442 million. A yearslong partner of ...

Two years ago, Biogen and partner Eisai secured accelerated ... attendees leaving the Westin St. Francis in San Francisco were met with protesters who accused the industry of putting profits ...

Jan 10 (Reuters) - Drugmaker Biogen (BIIB.O), opens new tab will buy all outstanding shares of Sage Therapeutics (SAGE.O), opens new tab that it does not already own for $7.22 apiece, a filing ...

Vanessa Leroy / Bloomberg via Getty Images Sage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.

SAN FRANCISCO (Reuters) - Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business development deals, the company's CEO ...

Sage Therapeutics (NASDAQ:SAGE) has confirmed that the Alzheimer’s drug developer Biogen (NASDAQ:BIIB) has offered to buy all the outstanding shares of common stock that it currently does not ...

BMO Capital says Biogen (BIIB) is looking for an early potential deal by offering to buy Sage Therapeutics (SAGE) for $7.22 per share. Such an offer reflects Biogen’s interest in reducing its ...

Biogen offers $7.22 per share to acquire Sage Therapeutics. Goldman Sachs projects Zurzuvae could reach $700 million in global sales by 2034. Get Pro-Level Earnings Insights Before the Market ...

Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) are expected to face another delay in launching their new Alzheimer's drug, lecanemab, in the EU after the European Commission on Friday asked the ...